How does 2696's PE Ratio compare to its peers?

2696 is good value based on its Price-To-Earnings Ratio (14.8x) compared to the peer average (60.6x).

How does 2696's PE Ratio compare vs other companies in the Asian Biotechs Industry?

2696 is good value based on its Price-To-Earnings Ratio (14.8x) compared to the Asian Biotechs industry average (33x).

What is 2696's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2696 is expensive based on its Price-To-Earnings Ratio (14.8x) compared to the estimated Fair Price-To-Earnings Ratio (11.3x).

What is the Fair Price of 2696 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

2696 (HK$20.3) is trading below our estimate of [[fair value]] (HK$80.98)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Shanghai Henlius Biotech (SEHK:2696) - Stock Price, News & Analysis

2696 Stock Overview

Engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. More details

2696 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	3/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 74.9% below our estimate of its fair value

Earnings are forecast to grow 11.54% per year

Became profitable this year

Risk Analysis

Has a high level of debt

Shanghai Henlius Biotech, Inc. Competitors

Shanghai Haohai Biological Technology

SEHK:6826

HK$14.8b

3SBio

SEHK:1530

HK$13.8b

Shandong Boan Biotechnology

SEHK:6955

HK$4.6b

TOT BIOPHARM International

SEHK:1875

HK$1.5b

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Henlius Biotech
Historical stock prices
Current Share Price	HK$20.30
52 Week High	HK$23.45
52 Week Low	HK$11.20
Beta	0.83
11 Month Change	-7.94%
3 Month Change	-11.35%
1 Year Change	36.06%
33 Year Change	-39.94%
5 Year Change	-50.97%
Change since IPO	-58.95%

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22

Shareholder Returns

	2696	HK Biotechs	HK Market
7D	0.2%	1.5%	0.4%
1Y	36.1%	-11.2%	12.0%

Return vs Industry: 2696 exceeded the Hong Kong Biotechs industry which returned -11.2% over the past year.

Return vs Market: 2696 exceeded the Hong Kong Market which returned 12% over the past year.

Price Volatility

Is 2696's price volatile compared to industry and market?
2696 volatility
2696 Average Weekly Movement	1.7%
Biotechs Industry Average Movement	10.9%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Stable Share Price: 2696 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2696's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2010	3,546	Jason Zhu	www.henlius.com

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer; and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous-cell carcinomas, gastric cancer, small cell lung cancer, hepatocellular carcinoma, metastatic colorectal cancer, solid tumors, SCCHN, sqNSCLC, hepatocellular carcinoma, and esophageal squamous cell carcinoma; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53, and HLX51 to treat solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; and HLX14 to treat osteoporosis.

Shanghai Henlius Biotech, Inc. Fundamentals Summary

How do Shanghai Henlius Biotech's earnings and revenue compare to its market cap?
2696 fundamental statistics
Market cap	HK$11.06b
Earnings (TTM)	HK$744.08m
Revenue (TTM)	HK$6.06b

14.8x

P/E Ratio

1.8x

P/S Ratio

Is 2696 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2696 income statement (TTM)
Revenue	CN¥5.64b
Cost of Revenue	CN¥1.51b
Gross Profit	CN¥4.13b
Other Expenses	CN¥3.44b
Earnings	CN¥692.34m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.27
Gross Margin	73.23%
Net Profit Margin	12.27%
Debt/Equity Ratio	147.0%

How did 2696 perform over the long term?

See historical performance and comparison

2696 Stock Overview

Rewards

Risk Analysis

Shanghai Henlius Biotech, Inc. Competitors

SEHK:6826

HK$14.8b

SEHK:1530

HK$13.8b

SEHK:6955

HK$4.6b

SEHK:1875

HK$1.5b

Price History & Performance

Recent News & Updates

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC)

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Receives Positive Opinion from the Committee Formedicinal Products for Human Use (Chmp)Of the European Medicines Agency (Ema)

Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of Pembrolizumab Biosimilar HLX17 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection)

Recent updates

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC)

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Receives Positive Opinion from the Committee Formedicinal Products for Human Use (Chmp)Of the European Medicines Agency (Ema)

Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of Pembrolizumab Biosimilar HLX17 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection)

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Announces Company Secretary Changes

Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024

Shanghai Henlius Biotech, Inc. Announces the First Patient Dose in A Phase 2 Clinical Trial of HLX53

Shanghai Henlius Biotech, Inc. Announces International Multicentre Phase 3 Clinical Trial for the First-Line Treatment of Metastatic Colorectal Cancer in Japan

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26